Measurement of conatumumab-induced apoptotic activity in tumors by fine needle aspirate sampling (Q33630657)

28 July 2017

title

Measurement of conatumumab-induced apoptotic activity in tumors by fine needle aspirate sampling (English)

1 reference

28 July 2017

0 references

10

Roy Herbst

1 reference

28 July 2017

Stephen J Zoog

1

1 reference

28 July 2017

Connie Y Ma

2

1 reference

28 July 2017

Paula J Kaplan-Lefko

3

1 reference

28 July 2017

Jennifer M Hawkins

4

1 reference

28 July 2017

Jodi Moriguchi

5

1 reference

28 July 2017

Lei Zhou

6

1 reference

28 July 2017

Yang Pan

7

1 reference

28 July 2017

Cheng-Pang Hsu

8

1 reference

28 July 2017

Greg Friberg

9

1 reference

28 July 2017

John Hill

11

1 reference

28 July 2017

Gloria Juan

12

1 reference

28 July 2017

publication date

1 September 2010

1 reference

28 July 2017

1 reference

28 July 2017

volume

77

1 reference

28 July 2017

issue

9

1 reference

28 July 2017

page(s)

849-860

1 reference

Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

Are fine-needle breast aspirates representative of the underlying solid tumour? A comparison of receptor levels, ploidy and the influence of cytokeratin gates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

Apo2L/TRAIL and its death and decoy receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

The receptor for the cytotoxic ligand TRAIL

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

The CD95(APO-1/Fas) DISC and beyond

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5.

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

The active caspase-8 heterotetramer is formed at the CD95 DISC

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO.

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

Targeting death receptors in cancer with Apo2L/TRAIL.

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

Value of ancillary studies in fine-needle aspiration biopsy

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

Comparison of the results of immunocytochemical assays for biologic variables on preoperative fine-needle aspirates and on surgical specimens of primary breast carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

Endoscopic ultrasound-guided fine-needle aspiration: sampling, pitfalls, and quality management

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

Measurement of signaling pathway activities in solid tumor fine-needle biopsies by slide-based cytometry.

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

Measurement of markers for breast cancer in a model system using laser scanning cytometry

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

Measurement of proliferation marker Ki67 in breast tumour FNAs using laser scanning cytometry in comparison to conventional immunocytochemistry

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

Clinical applications of slide-based cytometry--an update.

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

Immunocytochemical evaluation of HER-2/neu on fine-needle aspirates from primary breast carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

Proliferative activity in invasive breast carcinoma: a comprehensive comparison of MIB-1 immunocytochemical staining in aspiration biopsies to image analytic, flow cytometric and histologic parameters

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

Large B-cell lymphomas: fine-needle aspiration plays an important role in initial diagnosis of cases which are falsely negative by flow cytometry

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

Evaluation of the CD34 and CD10 immunostains using a two-color staining protocol in liver fine-needle aspiration biopsies

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

In biomarkers we trust?

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

Biomarkers in drug discovery and development

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

Biomarker discovery and validation

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

Use of specimen mammography-guided FNA (fine-needle aspirates) for flow cytometric multiple marker analysis and immunophenotyping in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.20940

7 January 2021

Identifiers

DOI

10.1002/CYTO.A.20940

1 reference

28 July 2017

1 reference